Strata Critical Medical, Inc. (SRTA) Fair Value 2026

SRTA · Services-Health Services ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 12 models active

Value Trap Risk

SAFE (24/100)

Quick Summary — As of 2026-07-13, Strata Critical Medical, Inc. (SRTA) trades at $5.01, approximately 184% above CirclFi’s Bayesian DCF fair value of $1.77. QOC: 6.0/10. Value Trap Risk: 24/100 (SAFE). 12/13 models active.

Key Facts

Ticker
SRTA
Price
$5.01
Quality Score
6.0/10
Value Trap Risk
24/100
Models Active
12/13
Last Updated
Strength: 12 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($5.01)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $1.77 -64.7%
Earnings Power Value
Medium Conviction
 $4.67 -6.8%
CUCE Ensemble
Low Conviction
 $2.35 -53.2%
First Chicago
High Conviction
 $0.64 -87.2%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Strata Critical Medical, Inc. (SRTA) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Strata Critical Medical, Inc.'s intrinsic value is estimated at $3.06. Trading at its current price of $5.01, the valuation engine raises significant caution: 10 of 12 models flag downside risk, projecting an average implied return of -38.8%. Model dispersion is worth noting: FTNN targets $5.98 (+19.3%), versus EROIC at $0.36 (-92.8%). This +112.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About SRTA?

12 of 13 models are currently active for SRTA. Of these, 2 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates SRTA's intrinsic value at $1.77, implying -64.7% downside from the current price. See which stocks rank higher →

How Does SRTA Rank in Services-Health Services?

Among 15 Services-Health Services stocks, SRTA ranks #9 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

Strata Critical Medical, Inc. operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is SRTA a Value Trap?

CirclFi's Value Trap algorithm assigns SRTA a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Strata Critical Medical, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Strata Critical Medical, Inc. earns a quality score of 6.0/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

The gap between the most bullish and bearish model spans +112.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every SRTA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across SRTA's 12 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Strata Critical Medical, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Services-Health Services Stocks Should You Also Analyze?

8 related Services-Health Services stocks with 13-model coverage

PNTGThe Pennant Group, Inc.QOC 9.2PRVAPrivia Health Group, Inc.QOC 8.3USPHU.S. Physical Therapy, Inc.QOC 8.0INNVInnovAge Holding Corp.QOC 6.7LFSTLifeStance Health Group, Inc.QOC 6.7TALKTalkspace, Inc.QOC 6.6WGSGeneDx Holdings Corp.QOC 6.1OMDAOmada Health, Inc.QOC 6.0

Read investment analysis: PNTG · PRVA · USPH · INNV · LFST

Frequently Asked Questions About Strata Critical Medical, Inc.

What is Strata Critical Medical, Inc.'s intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Strata Critical Medical, Inc. (SRTA) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $1.77. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is SRTA overvalued or undervalued right now?

At $5.01, 2 of 12 active models suggest SRTA may be undervalued, while 10 indicate potential overvaluation. The assessment depends on which methodology best fits Strata Critical Medical, Inc.'s business model in Services-Health Services.

What does a Quality of Company score of 6.0 mean for SRTA?

Strata Critical Medical, Inc.'s QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on SRTA?

CirclFi analyzes SRTA with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is SRTA a value trap in 2026?

Strata Critical Medical, Inc.'s Value Trap score is 24/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on SRTA.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access